Deciphera Pharmaceuticals, Inc. (DCPH): Price and Financial Metrics

Deciphera Pharmaceuticals, Inc. (DCPH)

Today's Latest Price: $46.03 USD

2.04 (-4.24%)

Updated Jan 26 6:55pm

Add DCPH to Watchlist
Sign Up

Overall POWR Rating

POWR Components:

 Trade Grade  Buy & Hold Grade  Peer Grade  Industry Rank

Industry Rank:

Ranked of 484 in Biotech

See all "A" rated Strong Buy stocks

DCPH Stock Summary

  • With a price/sales ratio of 115.95, Deciphera Pharmaceuticals Inc has a higher such ratio than 96.54% of stocks in our set.
  • Equity multiplier, or assets relative to shareholders' equity, comes in at 1.12 for Deciphera Pharmaceuticals Inc; that's greater than it is for just 9.87% of US stocks.
  • With a year-over-year growth in debt of 1,773.75%, Deciphera Pharmaceuticals Inc's debt growth rate surpasses 98.76% of about US stocks.
  • If you're looking for stocks that are quantitatively similar to Deciphera Pharmaceuticals Inc, a group of peers worth examining would be ZGNX, FPRX, LPTX, CKPT, and SRRK.
  • Visit DCPH's SEC page to see the company's official filings. To visit the company's web site, go to

DCPH Stock Price Chart Interactive Chart >

Price chart for DCPH

DCPH Price/Volume Stats

Current price $46.03 52-week high $71.11
Prev. close $48.07 52-week low $33.10
Day low $45.77 Volume 398,800
Day high $48.19 Avg. volume 410,381
50-day MA $56.86 Dividend yield N/A
200-day MA $54.18 Market Cap 2.62B

Deciphera Pharmaceuticals, Inc. (DCPH) Company Bio

Deciphera Pharmaceuticals LLC develops and manufactures kinase inhibitor treatments for cancer by cutting off the ability of tumor cells to thrive and spread. Its product pipeline includes Altiratinib (DCC-2701), a MET/TIE2/VEGFR2/TRK kinase inhibitor; DCC-2618, a pan-KIT inhibitor; Rebastinib, a TIE2/VEGFR1 kinase inhibitor; and LY3009120 (DP-4978), a pan-RAF inhibitor. The company was founded in 2003 and is based in Waltham, Massachusetts.

DCPH Latest News Stream

Event/Time News Detail
Loading, please wait...

DCPH Latest Social Stream

Loading social stream, please wait...

View Full DCPH Social Stream

Latest DCPH News From Around the Web

Below are the latest news stories about Deciphera Pharmaceuticals Inc that investors may wish to consider to help them evaluate DCPH as an investment opportunity.

Deciphera Pharmaceuticals (DCPH) Presents At 39th Annual J.P. Morgan Healthcare Conference - Slideshow

The following slide deck was published by Deciphera Pharmaceuticals, Inc. in conjunction with this event....

SA Transcripts on Seeking Alpha | January 20, 2021

Deciphera to expand geographic reach and clinical potential of ripretinib

Deciphera Pharmaceuticals (DCPH) intends to expand the market and clinical potential of ripretinib (QINLOCK®) in 2021, the company said in an announcement, issued in conjunction with its presentation at the 39th Annual J.P. Morgan Virtual Healthcare Conference.CEO of Deciphera, Steve Hoerter commented: “We are focused in 2021 on expanding both the...

Seeking Alpha | January 11, 2021

Deciphera Pharmaceuticals Provides Corporate Update and Highlights Key 2021 Corporate Milestones

WALTHAM, Mass.--(BUSINESS WIRE)--Deciphera Pharmaceuticals, Inc. (NASDAQ:DCPH), a commercial-stage biopharmaceutical company developing innovative medicines to improve the lives of people with cancer, today provided a corporate update and highlighted key 2021 milestones in conjunction with its presentation at the 39th Annual J.P. Morgan Virtual Healthcare Conference. The Company will webcast its presentation today at 9:10 AM ET at

Business Wire | January 11, 2021

Deciphera Pharmaceuticals to Present at the 39th Annual J.P. Morgan Healthcare Conference

WALTHAM, Mass.--(BUSINESS WIRE)--Deciphera Pharmaceuticals, Inc. (NASDAQ:DCPH) today announced that Steve Hoerter, President and Chief Executive Officer, will present at the 39th Annual J.P. Morgan Healthcare Conference on Monday, January 11, 2021 at 9:10 AM ET. A live webcast of the event will be available on the “Events and Presentations” page in the “Investors” section of the Company’s website at A replay of the webcast will b

Business Wire | January 5, 2021

DCPH Stock Forecast: Where Do Hedge Funds Stand?

In this article you are going to find out whether hedge funds think Deciphera Pharmaceuticals, Inc. (NASDAQ:DCPH) is a good investment right now. We like to check what the smart money thinks first before doing extensive research on a given stock. Although there have been several high profile failed hedge fund picks, the consensus picks […]

Yahoo | December 21, 2020

Read More 'DCPH' Stories Here

DCPH Price Returns

1-mo -20.06%
3-mo -21.94%
6-mo -0.73%
1-year -29.62%
3-year 74.09%
5-year N/A
YTD -19.34%
2020 -8.31%
2019 196.52%
2018 -7.41%
2017 N/A
2016 N/A

Continue Researching DCPH

Want to see what other sources are saying about Deciphera Pharmaceuticals Inc's financials and stock price? Try the links below:

Deciphera Pharmaceuticals Inc (DCPH) Stock Price | Nasdaq
Deciphera Pharmaceuticals Inc (DCPH) Stock Quote, History and News - Yahoo Finance
Deciphera Pharmaceuticals Inc (DCPH) Stock Price and Basic Information | MarketWatch

Get Free Updates

Join thousands of investors who get the latest news, insights and top rated picks from!

Page generated in 0.9125 seconds.